The cancer drug developer and Stanford spinout floated at the top of its range in an offering that could reach $129m.
Forty Seven, a US-based immuno-oncology drug developer spun out from Stanford University, has raised just over $112m in an initial public offering on the Nasdaq Global Select Market.
The company priced just over 7 million shares each at the top of the IPO’s $14 to $16 range. It opened at $15.31 on its first day of trading on Thursday before closing at $16.00 the following day.
Founded in 2015, Forty Seven is working on checkpoint therapies intended to treat…
